N-(芴甲氧羰基)甘氨酰氯 | 103321-49-9

• 物质功能分类: 生物化工 - 氨基酸及其衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: N-(芴甲氧羰基)甘氨酰氯
• 中文别名: N-FMOC-甘氨酰氯
• 英文名称: 9H-fluoren-9-ylmethyl (2-chloro-2-oxoethyl)carbamate
• 英文别名: Fmoc-Gly-Cl；FMOC-glycyl-chloride；Fmoc-glycinyl chloride；9H-fluoren-9-ylmethyl N-(2-chloro-2-oxoethyl)carbamate
• CAS: 103321-49-9
• 化学式: C₁₇H₁₄ClNO₃
• 分子量: 315.756
• InChiKey: HFWFBOCOXPEKBV-UHFFFAOYSA-N

物化性质

• 熔点：
  107-108 °C
• 沸点：
  492.3±28.0 °C(Predicted)
• 密度：
  1.317±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P260,P261,P264,P270,P271,P280,P301+P312,P301+P330+P331,P302+P352,P303+P361+P353,P304+P340,P305+P351+P338,P310,P312,P321,P322,P330,P363,P405,P501
• 危险品运输编号：
  3261
• 危险性描述：
  H302,H312,H314,H332
• 储存条件：
  -20°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Fmoc-gly-cl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Fmoc-gly-cl
CAS number: 103321-49-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C17H14ClNO3
Molecular weight: 315.8

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-(芴甲氧羰基)甘氨酰氯 在 盐酸羟胺 、 magnesium oxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以88%的产率得到(9H-fluoren-9-yl)methyl (2-(hydroxyamino)-2-oxoethyl)carbamate
  参考文献：
  名称：

  Direct synthesis of Fmoc protected amino acid hydroxamates from acid chlorides mediated by magnesium oxide

  摘要：

  The synthesis of Fmoc protected amino acid hydroxamates using Fmoc-amino acid chlorides and magnesium oxide is described. The method is simple and efficient, results in complete conversion, and gives good yields and satisfactory purity. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(03)00830-x
• 作为产物：
  描述：

  Fmoc-甘氨酸 在 氯化亚砜 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 0.5h， 生成 N-(芴甲氧羰基)甘氨酰氯
  参考文献：
  名称：

  评估新的形成三重态的人工核碱基作为针对HCV IRES IIId环的RNA配体。

  摘要：

  我们报告了两个新的人工核碱基支架的合成，1和2，具有足够的氢键供体和受体，分别用于U：A和C：G碱基对的分子识别。还报道了这些结构与各种氨基酸的连接以及这些人造核碱基-氨基酸缀合物作为针对HCV IRES IIId结构域的RNA配体的评估。化合物1e显示出最高的亲和力（Kd比新霉素低两倍）。而且，似乎这种相互作用在焓和熵上都是有利的。

  DOI：

  10.1016/j.bmcl.2017.02.061

文献信息

• Characterization of N^α-Fmoc-protected dipeptide isomers by electrospray ionization tandem mass spectrometry (ESI-MSⁿ): effect of protecting group on fragmentation of dipeptides
  作者：M. Ramesh、B. Raju、R. Srinivas、V. V. Sureshbabu、T. M. Vishwanatha、H. P. Hemantha

  DOI：10.1002/rcm.5076

  日期：2011.7.30

  and Y=CH(3)/H), have been characterized and differentiated by both positive and negative ion electrospray ionization ion-trap tandem mass spectrometry (ESI-IT-MS(n)). In contrast to the behavior of reported unprotected dipeptide isomers which mainly produce y(1)(+) and/or a(1)(+) ions, the protonated Fmoc-Xxx-Gly-OY, Fmoc-Ala-Xxx-OY and Fmoc-Xxx-Ala-OY yield significant b(1)(+) ions. These ions are formed

  Fmoc保护的二肽，Fmoc-Gly-Xxx-OY / Fmoc-Xxx-Gly-OY（Xxx = Ala，Val，Leu，Phe）和Fmoc-Ala-Xxx-OY / Fmoc-Xxx的一系列位置异构对-Ala-OY（Xxx = Leu，Phe）（Fmoc = [（9-芴基甲基）氧基]羰基和Y = CH（3）/ H）的特征在于，正离子和负离子电喷雾电离离子-阱串联质谱（ESI-IT-MS（n））。与主要产生y（1）（+）和/或a（1）（+）离子的未保护二肽异构体的行为相反，质子化的Fmoc-Xxx-Gly-OY，Fmoc-Ala-Xxx-OY和Fmoc-Xxx-Ala-OY产生明显的b（1）（+）离子。形成这些离子，大概具有稳定的质子化叠氮醌结构。但是，在N端带有Gly-的肽不会形成b（1）（+）离子。所有肽的[M + H]（+）离子都会经历McLafferty型重排，然后损失CO（2）形成[M
• [EN] COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR ADMINISTRATION OCULAIRE
  申请人：GRAYBUG VISION INC

  公开号：WO2020069353A1

  公开（公告）日：2020-04-02

  The present invention provides new prodrags of Sunitinib, Brinzolamide, and Dorzolamide and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (TOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

  本发明提供了新的Sunitinib、Brinzolamide和Dorzolamide的前药，以及用于治疗医学疾病的组合物，例如青光眼、与眼内压增高有关的疾病或异常（TOP）、需要神经保护的疾病、年龄相关性黄斑变性或糖尿病视网膜病变。
• N-Hydroxy and N-acyloxy peptides: synthesis and chemical modifications
  作者：James Lawrence、Laure Cointeaux、Pascal Maire、Yannick Vallée、Véronique Blandin

  DOI：10.1039/b606677a

  日期：——

  The preparation of a series of N-hydroxy peptides is described, along with their acylation on the oxygen of the pseudopeptide bond. Nineteen N-acyloxy peptides, first examples of this new class of pseudopeptides, were thus synthesized; they present a range of acyl groups, including N-protected amino acyl groups. Possibilities of elongation for these pseudopeptides were also investigated.

  本文描述了一系列N-羟基肽的制备及其在假肽键氧上的酰化反应。因此，合成了十九种N-酰氧基肽，这是这一新型假肽类化合物的首次实例；它们呈现出多种酰基，包括N-保护的氨基酸酰基。还探讨了这些假肽延长结构的可能性。
• [EN] 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE DE LA RATE (SYK) CONTENANT UN 2-PYRIDYL CARBOXAMIDE
  申请人：MERCK SHARP & DOHME

  公开号：WO2013052394A1

  公开（公告）日：2013-04-11

  The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

  本发明提供了一些含有2-吡啶甲酰胺的化合物，其化学式为(I)或药用可接受的盐，其中A和B按本发明定义。本发明还提供了包含这些化合物的药物组合物，以及使用这些化合物来治疗由脾酪氨酸激酶（Syk）介导的疾病或状况的方法。
• Synthesis and metal complexation properties of Ph-DTPA and Ph-TTHA: novel radionuclide chelating agents for use in nuclear medicine
  作者：S�bastien G. Gouin、Jean-Fran�ois Gestin、Laurence Monrandeau、Fabienne Segat-Dioury、Jean Claude Meslin、David Deniaud

  DOI：10.1039/b413758b

  日期：——

  We wish to report the synthesis and metal complexation properties of new radionuclide chelating agents for use in nuclear medicine. The strategy includes the facile preparation of rigid analogues of DTPA and TTHA possessing an aromatic ring. The aromatic structure used increased the stability of the complexes formed (pre-organization concept) and they are easily functionalised for attaching to any

  我们希望报告用于核医学的新型放射性核素螯合剂的合成和金属络合特性。该策略包括容易制备具有芳香环的DTPA和TTHA的刚性类似物。所用的芳族结构提高了所形成的配合物的稳定性（预组织概念），并且易于官能化以连接至任何载体。以苯二胺为起始原料，通过五个步骤，分别获得了聚氨基聚羧酸Ph-DTPA（5a）和Ph-TTHA（5b），总产率分别为42％和20％。该合成过程中的关键步骤是分别制备三氨基和四氨基化合物3a和3b。为了评估两种配体与不同金属（（111）In，（153）Sm，（90）Y，（177）Lu，（213）Bi，（225）Ac）络合的能力，除了适用于核医学外，我们还使用了许多补充测试。我们能够证明在弱酸性介质中Ph-DTPA（5a）与多种放射性核素的高络合能力。体外稳定性研究表明，Ph-DTPA与（111）In在人血清中具有很高的稳定性，这是所有医学应用的必要条件。Ph-DTPA（5a）的质子化常数（log